## Correct Answer: B. Atracurium Atracurium is a benzylisoquinolinium compound that undergoes **Hofmann elimination** (temperature- and pH-dependent degradation) and ester hydrolysis. During this metabolism, it releases **histamine** from mast cells and basophils, causing the characteristic clinical triad of flushing, rashes (urticaria), and hypotension. The flushing and rashes over the neck and anterior chest are pathognomonic for atracurium-induced histamine release. This reaction is dose-dependent and more pronounced with rapid IV bolus administration. In Indian clinical practice, atracurium is widely used because it does not depend on hepatic or renal metabolism—a critical advantage in patients with organ dysfunction common in Indian populations (cirrhosis, chronic kidney disease). However, the histamine release remains a significant drawback, especially in hemodynamically unstable patients or those with reactive airway disease. The reaction typically occurs within seconds to minutes of administration and can be mitigated by slow infusion, premedication with H1/H2 blockers, or switching to cisatracurium, which is a stereoisomer of atracurium with minimal histamine release. ## Why the other options are wrong **A. Cisatracurium** — Cisatracurium is the active stereoisomer of atracurium that undergoes the same Hofmann elimination and ester hydrolysis but with **significantly reduced histamine release** (approximately 15% of atracurium's release). It was specifically developed to overcome atracurium's histamine-related side effects. While it is metabolized similarly, the structural modification makes it the preferred choice in patients at risk for histamine reactions. This is a common NBE trap—students may confuse the two drugs because they share the same elimination pathway. **C. Pancuronium** — Pancuronium is a steroidal neuromuscular blocker that undergoes hepatic metabolism and renal excretion. It does **not cause histamine release** and is actually associated with sympathomimetic effects (tachycardia and hypertension due to vagolytic properties). It would not produce the flushing and rashes described in the question. Pancuronium is contraindicated in patients with hepatorenal dysfunction, making it less suitable for Indian populations with high prevalence of liver disease. **D. Vecuronium** — Vecuronium is a steroidal neuromuscular blocker that undergoes hepatic metabolism and biliary excretion. Like pancuronium, it does **not cause histamine release** and produces minimal cardiovascular effects. It is a non-depolarizing agent with intermediate duration and is commonly used in Indian operating theatres, but it would not explain the acute flushing and rashes. The absence of histamine release makes this option incorrect for this clinical presentation. ## High-Yield Facts - **Atracurium** causes **histamine release** leading to flushing, rashes, and hypotension—dose-dependent and preventable by slow infusion or H1/H2 blockade. - **Hofmann elimination** (temperature/pH-dependent) and **ester hydrolysis** are atracurium's unique elimination pathways—independent of liver/kidney function, ideal for organ dysfunction. - **Cisatracurium** is the active stereoisomer with **≤15% histamine release** of atracurium—preferred alternative when histamine reaction is a concern. - **Steroidal blockers** (pancuronium, vecuronium) undergo hepatic/biliary metabolism and do **not release histamine**—contraindicated in hepatorenal failure. - **Rapid IV bolus** of atracurium increases histamine release risk; **slow infusion over 30–60 seconds** reduces reaction severity in Indian clinical practice. ## Mnemonics **ATRACURIUM = Histamine Release** **A**trac = **A**llergy-like (flushing, rashes) | **T**emperature-dependent (Hofmann) | **R**apid bolus worsens it | **A**void in reactive airway disease | **C**isatracurium is the safer isomer. **Non-Histamine Blockers: PAVE** **P**ancuronium, **A**tracurium's isomer (cisatracurium), **V**ecuronium, **E**xclude histamine release—only atracurium (not cisatracurium) releases histamine. ## NBE Trap NBE pairs atracurium with cisatracurium to test whether students know that cisatracurium (the active stereoisomer) has **minimal histamine release** despite sharing the same elimination pathway. Students who only memorize "Hofmann elimination = atracurium" may incorrectly choose cisatracurium, missing the critical structural difference that reduces histamine release. ## Clinical Pearl In Indian operating theatres, atracurium's independence from hepatic/renal metabolism makes it invaluable for cirrhotic or chronically ill patients—but the histamine release remains a real intraoperative hazard. Slow infusion (30–60 seconds) and premedication with ranitidine 50 mg IV are standard practice to prevent the flushing and rashes seen in this case. _Reference: KD Tripathi Pharmacology Ch. 10 (Neuromuscular Blocking Agents); Harrison Principles of Internal Medicine Ch. 476 (Anesthesia)_
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.